10-Q · May 15, 2026
Annovis Bio reported a challenging Q1 2026, with a revenue of $0.0 and a diluted EPS loss of $0.63, falling short of the expected loss of $0.35. Operating expenses surged to $18 million, primarily driven by increased…
Earnings analysis · 10-Q
ANVS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Annovis reported $0 revenue and diluted EPS of $(0.40), improving by $0.23 from $(0.63) in the prior quarter and exceeding the $(0.46) consensus estimate. Clinical execution was constructive, with full enrollment of the…
Read full summary
Annovis reported $0 revenue and diluted EPS of $(0.40), improving by $0.23 from $(0.63) in the prior quarter and exceeding the $(0.46) consensus estimate. Clinical execution was constructive, with full enrollment of the 850-patient Alzheimer’s Phase 3 trial and 266 Parkinson’s extension-study patients enrolled. However, the $14.8 million net loss and $18.7 million cash balance keep liquidity and financing risk elevated, and the 10-Q provides no numeric financial guidance.
Reported figures
- Earnings per share
- $-0.4
What stood out
-
EPS improved and beat consensus
Revenue remained $0, while diluted EPS improved to $(0.40) from $(0.63) in 2026Q1, a $0.23 sequential improvement, and beat the $(0.46) consensus estimate by $0.06.
-
Alzheimer’s trial fully enrolled
The pivotal Alzheimer’s Phase 3 trial reached full enrollment of 850 patients, supporting advancement of the company’s lead clinical program.
-
Parkinson’s extension advanced
The Parkinson’s open-label extension study reached 266 enrolled patients, indicating continued clinical-program execution.
What to watch
-
No revenue and sizable net loss
The company reported $0 revenue and a $14.8 million net loss for the quarter, underscoring its ongoing pre-commercial operating profile.
-
Liquidity remains a key risk
Cash was $18.7 million, leaving liquidity dependent on additional financing or expense management while clinical programs continue.
-
Insider trading-plan terminations
Two directors or officers terminated Rule 10b5-1 plans covering an aggregate 321,426 shares: 270,000 shares for CEO Maria Maccecchini and 51,426 shares for Director Mark White.
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-Q; the filing states that there were no material changes to the risk-factor disclosures from the 2025 Form 10-K.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.